| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
RESEARCH |
Department of Anatomy, Embryology, Histology and Medical Physics, Ghent University, L. Pasteurlaan 2, B-9000 Ghent, Belgium, 1 Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185, B-9000 Ghent, Belgium and 2 Infertility Centre, Department of Obstetrics and Gynaecology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
Correspondence should be addressed to M Cornelissen; Email: ria.cornelissen{at}ugent.be
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The protocols for ES cell line derivation are relatively straightforward; the starting material is either dissociated morulae (Eistetter 1989), intact blastocysts (Evans & Kaufman 1981), or the ICM (Martin 1981). The long-time maintenance of mouse ES cells is achieved in the presence of a feeder cell layer and/or leukemia inhibitory factor (LIF) (Williams et al. 1988). Mouse ES cells are pluripotent embryo-derived cells with a large clear nucleus containing one or more prominent nucleoli and little cytoplasm. They are characterized by high levels of intracellular alkaline phosphatase (ALP), presentation of specific cell surface glycoproteins such as the stage-specific embryonic antigen (SSEA)-1 (Solter & Knowles 1978), presence of the transcription factor Oct-4 (Schöler et al. 1989), a high telomerase activity (Thomson et al. 1998), and a short G1 phase of the cell cycle (Rohwedel et al. 1996). These properties, except the presence of Oct-4, are characteristic of, but not specific for, pluripotent stem cells. Other essential characteristics include growth as multicellular colonies, normal and stable karyotypes, prolonged undifferentiated proliferation, and the potential to differentiate into derivatives of all three embryonic germ layers even after prolonged culture (Shamblot et al. 1998, Thomson et al. 1998). Pluripotent stem cell lines sharing most of these characteristics have also been reported from chicken, mink, hamster, pig, rhesus monkey, common marmoset (Shamblot et al. 1998), and man (Thomson et al. 1998).
Although the derivation of ES cells from certain mouse strains is relatively straightforward, the maintenance of pluripotency during and after derivation is often less successful (Buehr & Smith 2003). According to Evans & Kaufman (1981), the success might depend on three critical factors: (1) the exact stage at which pluripotent cells, capable of growth in tissue culture exist in the embryo; (2) explantation of a sufficiently large number of these precursor cells from the embryo; and (3) culture conditions most conducive to multiplication rather than differentiation of these embryonic cells. Oct-4 is expressed only in pluripotent lineages and is considered a key factor in maintenance of pluripotency in vivo and in vitro (Niwa 2001).
Mouse Oct-4 (also called Oct-3 and NF-A3) is a 352 amino acid protein belonging to Class V of Pit-Oct-Unc family that regulates the expression of target genes by binding to the octamer motif ATGCAAAT within their promoter or enhancer regions (Herr & Cleary 1995). Oct-4 has a unique pattern of RNA expression, which suggests a role in the regulation of early embryonic events. Oct-4 expression patterns in the mouse suggest that Oct-4 is involved in the initial formation, self-renewal, and maintenance of pluripotent cells (Nichols et al. 1998, Niwa 2001). At the blastocyst stage, Oct-4 protein expression becomes restricted to the cells of ICM (Pesce & Shöler 2001) but is downregulated, however, during differentiation of these cells. Oct-4 expression is further restricted to primordial germ cells after day 8 of gestation (Rosner et al. 1990, Schöler et al. 1990). In vitro, expression of Oct-4 has also been confirmed in other mouse pluripotent cells, undifferentiated ES cells, embryonal carcinoma (EC) cells, and embryonic germ cells (Niwa et al. 2000, Tanaka et al. 2002). Loss of pluripotency on spontaneous or induced differentiation has been correlated with progressive loss of Oct-4 expression. The expression of Oct-4 becomes down-regulated in ES and EC cells upon exposure to retinoic acid at concentrations that induce differentiation (Abdel-Rahman et al. 1995). Even more, the rapid loss of Oct-4 during culture of rodent blastocysts was a limiting factor in deriving pluripotent ES cell lines (Buehr et al. 2003).
Since in vitro culture may be influencing Oct-4 expression, we wanted to investigate to which extent blastocysts cultured in vitro from the zygote stage are capable of expressing Oct-4 and generating ES cell lines. In the present study, we describe the establishment and characterization of mouse ES cells derived from in vivo and in vitro cultured blastocysts with respect to ALP, SSEA-1, and Oct-4 expression and their capacity to differentiate in cells of the three germ layers. We studied the presence of Oct-4 in the outgrowths of these blastocysts after 6 days in culture. The levels of Oct-4 transcripts between in vivo and in vitro developed blastocysts were compared.
| Materials and Methods |
|---|
|
|
|---|
Embryo age is given in hours or days post hCG injection (p.i.).
Collection of mouse zygotes and blastocysts
Females were sacrificed by cervical dislocation, 22 h after hCG, and zygote cumulus complexes were isolated out of the swollen ampullae. Zygotes were denuded by a brief exposure to hyaluronidase (200 IU), washed thoroughly and the fertilized zygotes were cultured in groups of 10 in 60 µl drops of potassium simplex optimized medium (KSOM) in 60 mm dishes covered with light mineral oil in an atmosphere of 5% CO2 in air at 37 °C.
The KSOM medium (Erbach et al. 1994) was prepared in the laboratory, had a low-glucose content (0.2 mM), was supplemented with 4 mg/ml BSA and had an osmolarity of 265 mOsm. Freshly prepared media were stored at 4 °C and were used for up to 1 month.
They became blastocysts 4.5 days p.i. The in vivo grown blastocysts were collected from females killed on day 3.5 p.i. whose uteri were flushedwith M2 medium (Sigma).
Embryonic outgrowths and ES cell line derivation
Blastocysts derived from cultured zygotes were collected at 4.5 days p.i. and the in vivo blastocysts at 3.5 days p.i. The blastocysts were initially explanted individually on a feeder layer of mytomicin C-inactivated confluent mouse embryonic fibroblasts (MEFs) in a 96-well plate (Greiner, Wemmel, Belgium). MEF were obtained from 12.5 days postcoitus mouse embryos as described in detail elsewhere (Schoonjans et al. 2003).
Culture of blastocyst outgrowths on MEF was done in Dulbeccos modified eagle medium supplemented with 0.1 mM ß-mercaptoethanol, 10% Knockout serum replacement, 0.1 mM nonessential amino acids (Gibco BRL, Life technologies) and 1000 IU/ml LIF (ESGRO, Chemicon International, Asse-Relegem, Belgium). After culture for 6 days on MEF, ICM outgrowths were disaggregated by trypsinization and grown further on new feeder layers. After disaggregation, the cells were plated in culture. Medium was changed daily and the cells growing in colonies, designated as mouse ES cells, were split every 2 days and passaged by replating onto dishes with fresh MEF.
Generation of embryoid bodies (hanging drop method)
Embryoid bodies (EBs) were prepared using the hanging drop method. Once secondary ES cell cultures reached confluency, the ES cell colonies were disaggregated using trypsin and resuspended in differentiation medium (
MEM containing 10% FCS and 100 µM ascorbic acid (Sigma)) at a concentration of 40 000 cells/ml. Twenty microliter drops of the suspension were placed on the lid of a 100 mm plastic culture dish (Greiner). The lid was turned upside down and placed on the bottom part which was filled with PBS and then incubated at 37 °C with 5% CO2 for 2 days.
The EBs were transferred on day 3 of culture into another plastic culture dish containing 8 ml differentiation medium. EBs were further cultivated in suspension for 3 days to obtain well-formed EBs. At day 5, the resulted EBs were plated individually into 24-well tissue culture plates (Greiner) to study differentiation into the three germ layers.
Immunostaining
Stem cell markers
Oct-4.
Embryonic outgrowths were fixed with acetone (20 °C) during 5 min. The outgrowths were sampled for both kinds of matured blastocysts. Nonspecific staining was blocked with 2% BSA, 0.2% Tween and anti-rabbit serum in PBS during 30 min. The outgrowths were incubated overnight with the primary mouse MAB (1:50) raised against a recombinant protein corresponding to amino acid 1134 of human Oct-4 (C10) (sc-5279) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After extensive washing, outgrowths were exposed to biotinylated rabbit anti-mouse secondary antibody. After reaction with the horse radish peroxidase (HRP)-labeled streptavidin, localization of antigens was visualized by diaminobenzidine (DAB).
The same procedure was performed on the cell lines to characterize them as ES cells.
Alkaline phosphatase.
ALP expression was determined by staining with a diagnostic kit ALP substrate kit III (Vector Laboratories, Burlingame, CA, USA) according to the manufacturers instructions.
Stage-specific embryonic antigen-1.
Embryonic cells grown on feeder layers on plastic coverslips were fixed during 5 min with acetone (20 °C), washed with PBS, incubated with blocking serum containing 2% BSA, 0.2% Tween and anti-goat serum during 30 min and then incubated with the primary MAB MC-480 (Hybridoma Data Bank, University of Iowa, Iowa City, IA, USA) in a humidified chamber overnight at 4 °C. The cultures were washed with PBS, and incubated with goat anti-mouse IgM antibody conjugated with fluorescein isothiocyanate (Sigma) for 1 h, washed with PBS, embedded in glycerol-containing propidium iodide, and investigated by a confocal laser scanning microscopy system (Radiance 2100 blue laser diode, BioRad). All incubations were carried out in the presence of 2% BSA.
Differentiation markers
To confirm that the ES cells were able to differentiate into three germ layers, we performed immunohistochemistry on the plated EBs. We used the markers alpha fetoprotein (AFP) for endodermal cells,
-smooth muscle actin for mesodermal cells and neurofilament for ectodermal cells. After 4 weeks of differentiation, the EBs were fixed with acetone (20 °C) during 5 min. Nonspecific staining was blocked with 2% BSA, 0.2% Tween and anti-rabbit serum in PBS during 30 min. The EBs were incubated for 2 h with the primary goat polyclonal antibody AFP (1:100) (sc-8108) (Santa Cruz Biotechnology), primary monoclonal mouse anti-human smooth muscle actin (1:200) (DakoCytomation M0635) or with the primary anti-swine neurofilament protein (1:100) (DakoCytomation M0726). After extensive washing, EBs were exposed to biotinylated goat anti-mouse or rabbit anti-mouse secondary antibody. After the reaction with HRP-labeled streptavidin, localization of antigens was visualized by DAB.
RNA extraction and cDNA preparation
Three maturation conditions of blastocysts with regard to Oct-4 expression were compared: (1) blastocysts obtained from cultured zygotes (in vitro 4.5 days p.i.), (2) blastocysts directly flushed from the uterus (in vivo 3.5 days p.i.), and (3) blastocysts flushed from the uterus after 3.5 days p.i. in vivo and cultured for 1 additional day to reach the same p.i. time as needed for the in vitro development (in vivo 4.5 days p.i.).
The total RNA was extracted from individual blastocysts using the Absolutely RNA Nanoprep Kit (Stratagene, La Jolla, CA, USA). The total RNA samples were subjected to DNase digestion.
The cDNAs were prepared using the SuperScript First Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturers instructions.
Quantitative real-time RT-PCR
Primers used for PCR amplification were purchased from Eurogentec (Liège, Belgium). The sequences are listed in Table 1
.
|
Reactions were incubated for 10 min at 95 °C, followed by 50 cycles of a two-step amplification procedure consisting of annealing/extension at 60 °C for 1 min and denaturated for 15 s at 95 °C. In each run, dilution series of cDNA from a B6D2 ES cell line were amplified to serve as a standard curve for the calculation of relative quantities of the target gene to the housekeeping gene. As negative controls water and mouse fibroblasts cDNA and as positive controls the B6D2 ES cell line cDNA and gDNA were used.
Statistical analysis
Data concerning the real-time PCR are expressed as median and interquartile. The MannWhitney U test was used for comparisons between unpaired groups. P-values less than 0.01 were considered statistically significant.
| Results |
|---|
|
|
|---|
Establishment and characterization of embryonic stem cell lines
The efficiency to derivate ES cell lines from in vivo blastocysts vs blastocysts cultured in vitro from zygotes is summarized in Table 2
. The number of cell lines obtained from the in vivo blastocysts is about twice the number obtained from the in vitro blastocysts. The cell lines designated as ES cell lines grew in small compact dense colonies. Stainings performed at passage 8 were positive for ALP, SSEA-1, and Oct-4. The histochemical detection of ALP, the immunohistochemical detection of SSEA-1 and Oct-4 are shown in Fig. 1
.
|
|
-smooth muscle actin (mesoderm) are shown in Fig. 2
|
|
|
In the 3.5 days p.i. in vivo blastocysts, the Oct-4 mRNA expression was significantly higher compared to the in vitro cultured blastocysts (see Fig. 4
).
|
| Discussion |
|---|
|
|
|---|
In spite of the widespread use of in vitro developed blastocysts, surprisingly little is known about their potential to give rise to ES cell lines. Nevertheless, the study of a model starting of in vitro developed blastocysts can have several advantages. First of all, the number of blastocysts, obtained from zygotes developed in vitro is higher than the number of blastocysts flushed in vivo. In our experiments, about 20 zygotes were collected per superovulated mouse. More than 80% of the zygotes developed to the blastocyst stage following culture in vitro, confirming their high developmental competence. In contrast, high variability is noticed in the yield of blastocysts flushed after in vivo development. Secondly, in vitro cultured blastocysts will be the only possible source for ES cells in human. Flushing of blastocysts in vivo is not an option in humans, but blastocysts can fairly easily be obtained through the techniques of assisted reproduction developed for infertility treatment. Even more, when therapeutic cloning is ever to be used clinically there is the need for successfully and routinely establishing cell lines from cloned blastocysts.
Our results showed a lower efficiency in establishing ES cell lines from in vitro vs in vivo developed blastocysts (17 vs 38%). The results for in vivo developed blastocysts are strain dependent (Kawase et al. 1994) and our results fall within the range published for other mouse strains. For example, about 30% of strain, 129 blastocysts cultured according to standard derivation procedures will give rise to ES cells (Brook & Gardner 1997, Robertson 1987).
The criteria used in our study to characterize ES cell lines were the expression of ALP, SSEA-1, and Oct-4 and their possibility to give rise to cells of the three germlayers. These properties are most commonly used to characterize pluripotent ES cells (Vassilieva et al. 2000). Among these markers, Oct-4 appears to be indispensable for pluripotent capacity both in the embryo and in the ES cell lines (Nichols et al. 1998, Niwa et al. 2000). It is assumed that continuous expression of Oct-4 in precursor cells is necessary throughout derivation of ES cell lines (Buehr & Smith 2003). For this reason, we checked whether the lower efficiency of ES cell derivation for in vitro developed blastocysts may be related to lower Oct-4 expression patterns. We tracked expression of Oct-4 in ICM outgrowths. Staining of Oct-4 was performed after 6 days in culture. This is the time point of trypsinization of the outgrowths for ES cell line derivation. Nearly, 32 and 55% of the outgrowths were Oct-4 positive for the in vitro and in vivo matured blastocysts respectively. It can be noticed that only about half of Oct-4 positive outgrowths gave rise to ES cell lines. This may be related to loss of Oct-4 positive cells during and after the first trypsinization, a critical and difficult step in stem cell derivation. Also, the level of expression of Oct-4 is likely to be critical. Although the outgrowths are considered as Oct-4 positive by immunohistochemistry, differences in expression levels between the positively stained outgrowths can exist. It is known that the level of Oct-4 is decisive for either pluripotency or differentiation (Niwa et al. 2000). It is described that blastocysts and outgrowths with low or absent Oct-4 are not able to give rise to ES cell lines (Boiani et al. 2002). Other studies show that subtle variations in the level of Oct-4, not only below but also above the normal level can result in differentiation. Also, culturing blastocysts under standard ES cell derivation conditions can cause a decline in the number of Oct-4 expressing cells (Buehr & Smith 2003). In our experiments, we observed a decrease in Oct-4 expression during the culture period preceding the trypsinization time point, while after 3 days of culture still 80% of all the outgrowths expressed Oct-4. According to Buehr & Smith (2003), this rapid loss of Oct-4 may underlie the difficulties often encountered in ES cell derivation. If, as seems likely true, ES cells are derived directly from the Oct-4 expressing cells, the keys to successful derivation may lie in conditions or treatment that allow to extend the time window of Oct-4 expression.
It was also considered interesting to investigate the amounts of Oct-4 in our starting material for ES cell line derivation, the in vivo and in vitro developed blastocysts. We performed real-time PCR on individual blastocysts. For the in vitro obtained blastocysts, PCR was performed 4.5 days p.i.; for the in vivo obtained blastocysts, PCR was done on freshly obtained blastocysts (3.5 days p.i.) and on blastocysts developed for 4.5 days p.i. Blastocysts developed in vitro from the zygote or developed in vivo did not show the same maturation stage after the same p.i. time period. To reach the expanded blastocyst stage starting from zygotes, 4.5 days p.i. were needed. At this time point, nearly all embryos reached the expanded blastocyst stage (after 3.5 days p.i. only morulae and very early blastocysts were present in the in vitro culture condition). However, when we wanted to obtain blastocysts developed in vivo, only flushing after 3.5 days p.i. time resulted in a good yield which is a p.i. time commonly used to derive mouse ES cell lines from in vivo developed blastocysts (Hogan et al. 1994). At this time point, we observed a wide variation in maturation stages among the flushed embryos. Expanded blastocysts were selected for real-time PCR but also early blastocysts and morulae were present. After 1 day in culture (at day 4.5 p.i.), all embryos reached the expanded blastocyst stage. In order to explain this apparent growth retardation in vitro, we speculate that the oviduct secretes (an) essential growth factor(s) and/or amino acids needed by embryos for the activation of their embryonic genome to permit the subsequent development into healthy blastocysts and fetuses. These factors possibly explain the delay in development often observed in in vitro culture systems (Van der Auwera et al. 1999).
No significant differences in Oct-4 mRNA transcript levels were found between in vitro developed blastocysts 4.5 days p.i. and between 3.5 days p.i. blastocysts that were cultured in vitro for 1 day. In contrast, significantly higher Oct-4 levels were detected in the freshly obtained in vivo developed blastocyst (3.5 days p.i.). This suggests a rapid loss of Oct-4 expression in vitro. According to Kiessling et al.(1991), embryos that develop in vitro from the two-cell stage exhibit fewer total cells; the percent of cells in mitosis and the ratio of cells in the ICM to those in the trophoblast layer are the same as in in vivo embryos with the same cell number. This can suggest that the expression in Oct-4 in one cell of the ICM is higher in the in vivo blastocyst than in the in vitro maturated blastocyst, but this has to be confirmed by doing real time PCR on isolated ICM.
| Conclusion |
|---|
|
|
|---|
| Acknowledgements |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Abdel-Rahman B, Fiddler M, Rappolee D & Pergament E 1995 Expression of transcription regulating genes in human preimplantation embryos. Human Reproduction 10 27872792.
Boiani M, Eckardt S, Schöler HR & McLaughlin KJ 2002 Oct-4 distribution and level in mouse clones: consequences for pluripotency. Genes and Development 16 (Supplement 10) 12091219.
Brook FA & Gardner RL 1997 The origin and efficient derivation of embryonic stem cells in the mouse. PNAS 94 57095712.
Buehr M & Smith A 2003 Genesis of embryonic stem cells Philosophical Transactions: Biological Sciences. Royal Society London, B 358 13971402.
Buehr M, Nichols J, Stenhouse F, Mountford P, Greenhalgh CJ, Kantachuvesiri S, Brooker G, Mullins J & Smith AG 2003 Rapid loss of Oct-4 and pluripotency in cultured rodent blastocysts and derivative cell lines. Biology of Reproduction 68 222229.
Eistetter HR 1989 Pluripotent embryonal stem cell lines can be established from disaggregated mouse morulae. Development Growth and Differentiation 31 275282.[CrossRef]
Erbach GT, Lawitts JA, Papaioannou VE & Biggers JD 1994 Differential growth of the mouse preimplantation embryo in chemically defined media. Biology of Reproduction 50 10271033.[Abstract]
Evans MJ & Kaufman M 1981 Establishment in culture of pluripotent cells from mouse embryo. Nature 292 154156.[CrossRef][Medline]
Herr W & Cleary MA 1995 The Pou domain: versatility in the transcriptional regulation by a flexible two-in-one DNA-binding domain. Genes and Development 9 16791693.
Hogan B, Beddington R, Constantini F & Lacy E 1994 Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Press.
Kawase E, Suemori H, Takahashi N, Okazaki K, Hashimoto K & Nakatsuji N 1994 Strain differences in establishment of mouse embryonic stem (ES) cell lines. International Journal of developmental Biology 38 385390.[ISI][Medline]
Kiessling AA, Davis HW, Williams CS, Sauter RW & Harrison LW 1991 Development and DNA polymerase activities in cultured preimlantation mouse embryos: comparison with embryos developed in vivo. Journal of Experimental Zoology 258 3447.
Martin GR 1981 Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma cells. PNAS 78 76347638.
Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H & Smith A 1998 Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95 379391.[CrossRef][ISI][Medline]
Niwa H 2001 Molecular mechanism to maintain stem cell renewal of ES cells. Cell structure and function 26 137148.[CrossRef][ISI][Medline]
Niwa H, Miyazaki J & Smith AG 2000 Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation, or self-renewal of ES cells. Nature Genetics 24 372376.[CrossRef][ISI][Medline]
Pesce M & Shöler HR 2001 Oct-4: Gatekeeper in the beginnings of the mammalian development. Stem Cells 19 271278.
Robertson EJ 1987 Embryo-derived Stem Cell Lines, Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Oxford, UK: IRL Press.
Rohwedel J, Sehlmeyer U, Shan J, Meister A & Wobus AM 1996 Primordial germ cell derived mouse embryonic germ (EG) cells in vitro resemble undifferentiated stem cells with respect to differentiation capacity and cell cycle distribution. Cell Biology International 20 579587.[CrossRef][ISI][Medline]
Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, Rigby PWJ & Staudt LM 1990 A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature 345 686692.[CrossRef][Medline]
Schöler HR, Hatzopoulos AK, Balling R, Suzuki N & Gruss P 1989 A family of octamer specific proteins present during mouse embryogenesis: Evidence for germline-specific expression of an Oct factor. European Molecular Biology Organization Journal 8 25432550.
Schöler HR, Dressler GR, Balling R, Rohdewohld H & Gruss P 1990 Oct-4: A germline-specific transcription factor mapping to the mouse t-complex. European Molecular Biology Organization Journal 9 21852195.
Schoonjans L, Kreemers V, Danloy S, Moreadith RW, Laroche Y & Collen D 2003 Improved generation of germline-competent embryonic stem cell lines from inbred mouse strains. Stem Cells 21 9097.
Shamblot MJ, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, Blumenthal PD, Huggins GR & Gearhart JD 1998 Derivation of pluripotentstem cells from cultured human primordial germ cells. PNAS 95 1372613731.
Smith AG 1998 Cell therapy: in search of pluripotency. Current Biology 8 802804.
Smith AG 2001 Embryo-derived stem cells: of mice and men. Annual Review of Cell and Developmental Biology 17 435462.[CrossRef][ISI][Medline]
Solter D & Knowles BB 1978 Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). PNAS 75 55655569.
Solter D & Gearhart J 1999 Putting stem cells to work. Science 283 14681470.
Tanaka TS, Kunath T, Kimber WL, Jaradat SA, Stagg CA, Usuda M, Yokota T, Niwa H, Rossant J & Ko MS 2002 Gene expression profiling of embryo-derived stem cells reveals candidate genes associated with pluripotency and lineage specificity. Genome Research 12 19211928.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS & Jones MJ 1998 Embryonic stem cell lines derived from human blastocysts. Science 282 11451147.
Van der Auwera I, Pijnenborg R & Koninckx PR 1999 The influence of in-vitro culture versus stimulated and untreated oviductal environment on mouse embryo development and implantation. Human Reproduction 14 25702574.
Vassilieva S, Guan K, Pich U & Wobus AM 2000 Establishment of SSEA-1- and Oct-4-expression rat embryonic stem-like cell lines and effects of cytokines of the IL-6 family on clonal growth. Experimental Cell Research 258 361373.[CrossRef][ISI][Medline]
Williams RL, Hilton DJ, Pease S, Wilson TA, Stewart CL, Gearing DP, Wagner EF, Metcalf D, Nicola NA & Gough NM 1988 Myeloid leuaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336 684687.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |